Predictors of the effectiveness of initial therapy with antimuscarinic agents in children with neurogenic urination disorders

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Almost a third of patients with neurogenic urinary disorders have a refractory nature to therapy with antimuscarinic agents. The aim of the current trial was to identify predictors of the effectiveness of initial therapy with antimuscarinic agents in children with neurogenic urination disorders. For this, a comprehensive analysis of clinical parameters and video urodynamic findings in children was made.

AIM: The purpose of this study was to identify predictors of the successful initial therapy with M-anticholinergic preparations in children with neurogenic urinary disorders. For this, results of a comprehensive analysis of initial clinical and video urodynamic parameters were used..

METHODS: A prospective longitudinal cohort study involved 62 patients, aged 1.8–18 years, with neurogenic urination. In addition to the standard examination, all patients underwent a video urodynamic examination at Laborite Delphis UDS-600 device with parallel cystography at Siemens X-ray C-arc (Siemens, Germany). By the obtained results, 52 out of 62 patients were prescribed antimuscarinic agents as the first line therapy. Therapy effectiveness was assessed in 3 months. Analysed parameters were age, presence/absence of self-catheterization, as well as presence/absence of vesicoureteral reflux (VUR) revealed at conventional retrograde urethrocystography and/or video urodynamic examination.

RESULTS: The multivariate regression analysis demonstrated that the risk of ineffective antimuscarinic therapy increases by 75,6% in patients with VUR revealed at retrograde uretrocystography, regardless of patient's age and self-catheterization (OR=0.244; 95% CI=0.063-0.937; p=0.040) and by 89.8% (OR=0.102; 95% CI=0.019-0.554; p=0.008) when VUR is detected at video urodynamic examination. Unlike patients with a positive effect (n=24; 50%), 24 patients (50%) who had no response to antimuscarinic therapy were younger (median age 8 years); they also were self-catheterized and had VUR revealed at video urodynamic examination. Outcomes of the prescribed therapy were not associated with other video urodynamic parameters. The identified significant predictors (age, self-catheterization and VUR at video urodynamic examination) have allowed to develop a model for predicting antimuscarinic therapy effectiveness before its administration. This model can promote a rational selection of patients for antimuscarinic therapy, as the first line therapy, with a high probability of positive outcome in 84.9% of patients.

CONCLUSION: When prescribing antimuscarinic agents, patient's age, self-catheterization, VUR revealed at retrograde urethrocystography and video urodynamic examination should be taken into account. Predictors of effective antimuscarinic therapy in children with neurogenic urinary disorders, which increase the likelihood of successful outcomes, are patient's age (over 12 years), no self-catheterization and no VUR at video urodynamic examination. Patients younger than 12 years, with self-catheterization and VUR are less likely to respond to antimuscarinic therapy.

Full Text

Restricted Access

About the authors

Sergey A. Shabaev

I.M. Sechenov First Moscow State Medical University (Sechenov University); G.N. Speransky Children's City Clinical Hospital No 9

Author for correspondence.
Email: pancef@icloud.com
ORCID iD: 0009-0000-2669-3413

MD

Russian Federation, Moscow; Moscow

Dmitry A. Morozov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: damorozov@list.ru
ORCID iD: 0000-0002-1940-1395
SPIN-code: 8779-8960

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Ivan I. Afukov

G.N. Speransky Children's City Clinical Hospital No 9

Email: dgkb9@zdrav.mos.ru
ORCID iD: 0000-0001-9850-6779
SPIN-code: 4284-4702

MD, Cand. Sci. (Medicine), Associate Professor

Russian Federation, Moscow

Vera V. Rostovskaya

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: rostovskaya_vera@mail.ru
ORCID iD: 0000-0002-3718-8911
SPIN-code: 6989-5041

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

References

  1. Khoshnood B, Loane M, de Walle H, et al. Long term trends in prevalence of neural tube defects in Europe: Population based study. BMJ. 2015;(351):h5949. EDN: XMOSXJ doi: 10.1136/bmj.h5949
  2. Demikova NS, Podolnaya MA, Lapina AS. Prevalence and time trends of neural tube defects in regions of the Russian Federation. Russ Bull Perinatol Pediatr. 2019;64(6):30–38. EDN: CNWGZA doi: 10.21508/1027-4065-2019-64-6-30-38
  3. Wyndaele JJ, Wyndaele M, Rapidi CA, Krassioukov A. What do X-ray images of the bladder during video urodynamics show us in patients with spinal cord injury? Spinal Cord. 2022;60(5):408–413. EDN: AFNVQH doi: 10.1038/s41393-022-00771-4
  4. Lin CC, Kuo HC. Video-urodynamic characteristics and predictors of switching from botulinum neurotoxin a injection to augmentation enterocystoplasty in spinal cord injury patients. Toxins. 2022;14(1):47. EDN: GLWGFF doi: 10.3390/toxins14010047
  5. Soygür T, Arikan N, Tokatli Z, Karaboga R. The role of video-urodynamic studies in managing non-neurogenic voiding dysfunction in children. BJU Int. 2004;93(6):841–843. EDN: FMKNIT doi: 10.1111/j.1464-410X.2003.04734.x
  6. Hoebeke P, van Laecke E, van Camp C, et al. One thousand video-urodynamic studies in children with non-neurogenic bladder sphincter dysfunction. BJU Int. 2001;87(6):575–580. EDN: BABZYX doi: 10.1046/j.1464-410x.2001.00083.x
  7. Van Batavia JP, Ahn JJ, Fast AM, et al. Prevalence of urinary tract infection and vesicoureteral reflux in children with lower urinary tract dysfunction. J Urol. 2013;190(4 Suppl):1495–1499. doi: 10.1016/j.juro.2013.02.016
  8. Azuero J, Becerra AM, Barrera Á, et al. Videourodynamics: Current indications, technique and considerations. Arch Espanoles Urol. 2021;74(7):664–675. (In Spanish).
  9. Franco I, Hoebeke P, Baka-Ostrowska M, et al. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: Results from two phase 3 prospective open-label studies. J Pediatr Urol. 2020;16(2):180.e1–180.e8. doi: 10.1016/j.jpurol.2019.12.012
  10. European Association of Urology Guidelines. Paediatric Urology. Edn. presented at the EAU Annual Congress Milan. In: Cloudfront [Internet]. Arnhem: EAU Guidelines Office; 2023 [cited 2024 Mar 15]. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/ EAU-Guidelines-on-Paediatric-Urology-2023.pdf
  11. Meijer EF, Nieuwhof-Leppink AJ, Dekker-Vasse E, et al. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program. J Pediatr Urol. 2015;11(1):21.e1-5. doi: 10.1016/j.jpurol.2014.06.024
  12. Kato T, Mizuno K, Nishio H, et al. Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: A case report. J Med Case Rep. 2021;15(1):86. EDN: QJPXAH doi: 10.1186/s13256-020-02564-w
  13. Kazanskaya IV, Vishnevsky EL, Ignatiev RO, Guseva NB. M-cholinolytics in rheabilitation of children with voiding disfunction and urnary bladder hyperactivity. Curr Pediatrics. 2006;2(5):65–68. EDN: KWPTOJ
  14. Morin F, Blais AS, Nadeau G, et al. Dual therapy for refractory overactive bladder in children: A prospective open-label study. J Urol. 2017;197(4):1158–1163. doi: 10.1016/j.juro.2016.11.101
  15. Khan MK, Vander Brink BA, de Foor WR, et al. Botulinum toxin injection in the pediatric population with medically refractory neuropathic bladder. J Pediatr Urol. 2016;12(2):104.e1-6. doi: 10.1016/j.jpurol.2015.08.018
  16. Baibikov RS, Shaderkina VA, Pogodina MA, et al. Endoscopic correction of vesico-ureteral reflux in children: Differentiated choice of method, material and its dosage. Exp Clin Urol. 2021;(4):114–130. EDN: ISSDAM doi: 10.29188/2222-8543-2021-14-4-114-130
  17. Dubrov VI, Strotsky AV. Results of laparoscopic extravesical antireflux operation in vesicoureteral reflux in children. Proceedings National Acad Sci Belarus. 2020;17(4):427–436. EDN: BNCVLU doi: 10.29235/1814-6023-2020-17-4-427-436
  18. Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children’s Continence Society. Neurourolog Urodynamic. 2016;35(4):471–481. doi: 10.1002/nau.22751
  19. Nitti VW, Kopp Z, Lin AT, et al. Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion. Neurourolog Urodynamic. 2010;29(4):652–657. doi: 10.1002/nau.20910
  20. Serati M, Braga A, Siesto G, et al. Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder. Urology. 2013;82(5):1044–1048. doi: 10.1016/j.urology.2013.08.006
  21. Serati M, Cantaluppi S, Coluccia AC, et al. Is urodynamic evaluation able to change and improve the management of women with idiopathic overactive bladder? Minerva Urol Nephrolog. 2021;73(6):823–830. EDN: KLFSJY doi: 10.23736/S2724-6051.20.03801-1
  22. Hsiao SM, Lin HH, Kuo HC. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome. Neurourolog Urodynamic. 2014;33(3):331–334. doi: 10.1002/nau.22394
  23. Naranjo-Ortiz C, Clemente-Ramos LM, Salinas-Casado J, Méndez-Rubio S. Urodynamic approach to female urinary incontinence refractory to treatment with anticholinergics. Arch Espanoles Urol. 2012;65(10):879–886.
  24. Schneider T, Marschall-Kehrel D, Hanisch JU, Michel MC. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients? Int J Clin Pract. 2010;64(9):1287–1293. doi: 10.1111/j.1742-1241.2010.02442.x
  25. Herschorn S, Kaplan SA, Sun F, Ntanios F. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents? Urology. 2014;83(5):1023–1029. doi: 10.1016/j.urology.2013.12.027
  26. Michel MC, Schneider T, Krege S, Goepel M. Does gender or age affect the efficacy and safety of tolterodine? J Urol. 2002;168(3):1027–1031. doi: 10.1016/S0022-5347(05)64567-3
  27. Sheyn D, Ju M, Zhang S, et al. Development and validation of a machine learning algorithm for predicting response to anticholinergic medications for overactive Bladder syndrome. Obstetrics Gynecol. 2019;134(5):946–957. doi: 10.1097/AOG.0000000000003517

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Graphical representation of the difference in parameters between patients of two groups depending on the effectiveness of M-anticholinergic therapy: a — median age; b — frequency of self–catheterization; c — average urine volume during self-catheterization (median); d — presence of vesicoureteral reflux by video urodynamic examination findings ; 0 — ineffective therapy; 1 — effective therapy; ПМР — vesicoureteral reflux.

Download (134KB)
Indexing metadata
3. Fig. 2. ROC analysis for model 2: a — the intersection point of sensitivity and specificity curves; b — the ROC curve.

Download (131KB)
Indexing metadata

Copyright (c) 2024 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies